OFFICE OF THE SECRETARY OF STATE

SHEMIA FAGAN SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE



ARCHIVES DIVISION STEPHANIE CLARK DIRECTOR

800 SUMMER STREET NE SALEM, OR 97310 503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 18-2021

CHAPTER 855 BOARD OF PHARMACY **FILED**

06/15/2021 3:08 PM ARCHIVES DIVISION SECRETARY OF STATE & LEGISLATIVE COUNSEL

FILING CAPTION: Compendia updated to incorporate recent Public Health and Pharmacy Formulary Advisory

Committee (PHPFAC) recommendations.

EFFECTIVE DATE: 06/15/2021

AGENCY APPROVED DATE: 06/09/2021

CONTACT: Rachel Melvin 800 NE Oregon St., Suite 150 Filed By:

971-673-0001 Portland,OR 97232 Rachel Melvin pharmacy.rulemaking@bop.oregon.go Rules Coordinator

٧

RULES:

855-020-0110, 855-020-0120, 855-020-0200, 855-020-0300

AMEND: 855-020-0110

NOTICE FILED DATE: 04/16/2021

RULE SUMMARY: Updates all protocols in the protocol compendia. Adds one new item to the formulary compendia.

CHANGES TO RULE:

855-020-0110

Prescribing Practices

- (1) A pharmacist located and licensed in Oregon may prescribe and dispense FDA-approved drugs and devices included on either the Formulary or Protocol Compendia, set forth in this Division. A pharmacist shall only prescribe a drug or device consistent with the parameters of the Formulary and Protocol Compendia, and in accordance with federal and state regulations.¶
- (2) A pharmacist must create, approve, and maintain policies and procedures for prescribing post-diagnostic drugs and devices or providing patient care services via implementation of pursuant to statewide drug therapy management protocols. The policies and procedures shall describe current and referenced clinical guidelines, and include but not be limited to:¶
- (a) Patient inclusion and exclusion criteria: ¶
- (b) Explicit medical referral criteria;¶
- (c) Care plan preparation, implementation, and follow-up;¶
- (d) Prescribing drugs and devices pursuant to the formulary and protocol compendia;¶
- (e) Patient education; and ¶
- (f) Provider notificationatient education; and ¶
- (e) Provider notification; and ¶
- (f) Maintaining confidentiality.¶
- (3) The pharmacist is responsible for recognizing limits of knowledge and experience and for resolving situations

beyond his or her pharmacist their expertise by consulting with or referring patients to another health care provider.¶

- (4) For each drug or device the pharmacist prescribes, the pharmacist must:¶
- (a) Assess patient and collect subjective and objective information, including the diagnosis for Formulary Compendia items, about the patient's health history and clinical status. The pharmacist's patient assessment shall be performed in a face-to-face, in-person interaction and not through electronic means; and ¶
- (b) Utilize information obtained in the assessment to evaluate and develop an individualized patient-centered care plan, pursuant to the statewide drug therapy management protocol and policies and procedures; and ¶
- (c) Implement the care plan, to include appropriate treatment goals, monitoring parameters, and follow-up; and \P
- (d) Provide notification, preferably via an interoperable information technology system, to the patient's identified primary care provider or other care providers when applicable, within five business days following the prescribing of a Compendia drug or device.¶
- (5) The pharmacist shall maintain all records associated with prescribing and other related activities performed for a minimum of 10 years, and a copy must be made available to the patient and provider upon request. Pharmacy records must be retained and made available to the Board for inspection upon request. Records must be stored onsite for at least one year and then may be stored in a secure off-site location if retrievable within three business days. Records and documentation may be written, electronic or a combination of the two.

Statutory/Other Authority: ORS 689.205

AMEND: 855-020-0120

NOTICE FILED DATE: 04/16/2021

RULE SUMMARY: Updates all protocols in the protocol compendia. Adds one new item to the formulary compendia.

CHANGES TO RULE:

855-020-0120

Prescribing Prohibited Practices

The responsibility and authority to prescribe pursuant to the Formulary and Protocol Compendia is upon the pharmacist. A pharmacist shall not prescribe a drug or device to self or immediate family members (1) A pharmacist may not prescribe a drug or device to self or a spouse, domestic partner, parent, guardian, sibling, child, aunt, uncle, grandchild and grandparent, including foster, in-law, and step relationships or other individual for whom a pharmacist's personal or emotional involvement may render the pharmacist unable to exercise detached professional judgment in prescribing pursuant to the Formulary and Protocol Compendia. ¶

(2) An intern may not prescribe a drug or device.

Statutory/Other Authority: ORS 689.205

Statutory/Other Authority, ONS 007.203

AMEND: 855-020-0200

NOTICE FILED DATE: 04/16/2021

RULE SUMMARY: Updates all protocols in the protocol compendia. Adds one new item to the formulary compendia.

CHANGES TO RULE:

855-020-0200

Formulary Compendium

A pharmacist may prescribe, according to regulations outlined ules in this Division, an FDA-approved drug and device listed in the following compendium, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. The diagnosis must be documented.¶

Devices and supplies:¶

- (1) Diabetic blood sugar testing supplies;¶
- (2) Injection supplies;¶
- (3) Nebulizers and associated supplies;¶
- (4) Inhalation spacers;¶
- (5) Peak flow meters;¶
- (6) International Normalized Ratio (INR) testing supplies;¶
- (7) Enteral nutrition supplies; and ¶
- (8) Ostomy products and supplies: and ¶
- (9) Non-invasive blood pressure monitors

Statutory/Other Authority: ORS 689.205

AMEND: 855-020-0300

NOTICE FILED DATE: 04/16/2021

RULE SUMMARY: Updates all protocols in the protocol compendia. Adds one new item to the formulary compendia.

CHANGES TO RULE:

855-020-0300

Protocol Compendium

A pharmacist may prescribe, via statewide drug therapy management protocol and according to regulationules outlined in this Division, an FDA-approved drug and device listed in the following compendium:¶

- (1) Continuation of therapy¶
- (a) A pharmacist may prescribe any non-controlled medication to extend a patient's prescription therapy to avoid interruption of treatment; and ¶
- (b) In such cases, a pharmacist shall only prescribe a drug quantity sufficient for the circumstances, not to exceed a 60-day supply, and no more than two extensions in a 12-month period per medication.¶
- (2) Conditions¶
- (a) Cough and cold symptom management¶
- (A) Pseudoephedrine products for patients 18 years of age and older, verified by positive identification, not to exceed 3.6 grams or a 60-count quantity per prescription, whichever is less, or a total of three prescriptions in a 12-month period. Pharmacist must review PDMP prior to issuing prescription and retain documentation of PDMP review: ¶
- (B) Benzonatate, for the treatment of cough, not to exceed a 7-day supply;¶
- (C) Short-acting beta agonists, not to exceed 1 inhaler with or without a spacer, or 1 box of nebulizer ampules, per year; (v. 06/2021)¶
- (2) Conditions¶
- (a) Cough and cold symptom management¶
- (A) Pseudoephedrine (v. 06/2021); ¶
- (B) Benzonatate (v. 06/2021);¶
- (C) Short-acting beta agonists (v. 06/2021); and ¶
- (D) Intranasal corticosteroids: (v. 06/2021)¶
- (b) Vulvovaginal candidiasis (VVC) Protocol (v. August 06/20201)¶
- (3) Preventative care ¶
- (a) Emergency Contraception, not including abortifacients. (v. 06/2021):¶
- (b) Male and female condoms: (v. 06/2021);¶
- (c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT Protocol (v. August 2020). A pharmacist is permitted to provide patient care services pursuant to this protocol only upon documented completion of a minimum of 2 hours of tobacco cessation continuing education. ¶
- (d) Travel Medications Protocol (v. August 2020). A pharmacist who meets criteria to immunize pursuant to OAR 855-019-0270 is permitted to provide patient care services pursuant to this protocol only upon documented completion of: minimum of 4 hour certificate for pharmacy-based travel medicine services intended for the pharmacist (one-time requirement), and minimum of 1 hour of travel medication continuing education every 24 months.¶
- (e) HIV Post-exposure Prophylaxis (PEP) Protocol (v. August 2020). A pharmacist is permitted provide patient care services pursuant to this protocol only upon documented completion of a comprehensive training program for the prescribing and dispensing of HIV prevention medications, to include related trauma-informed care. 06/2021):¶
- (d) Travel Medications Protocol (v. 06/2021) ¶
- (e) HIV Post-exposure Prophylaxis (PEP) Protocol (v. 06/2021); and ¶
- (f) HIV Pre-exposure Prophylaxis (PrEP) Protocol (v. December 2020). A pharmacist is permitted provide patient care services pursuant to this protocol only upon documented completion of a comprehensive training program

for the prescribing and dispensing of HIV prevention medications, to include related trauma-informed care. \P [Publications referenced are available from the agency 06/2021) \P

[Publications referenced are available for inspection in the office of the Board of Pharmacy per OAR 855-010-0021.]

Statutory/Other Authority: ORS 689.205